Abigail Beaney

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Eli Lilly’s Phase III trial with its oral weight loss pill, orforglipron, has met its primary endpoint, reducing A1C levels by up to 1.6%. In the first of several readouts expected from a Phase III programme, Lilly said its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) demonstrated significant efficacy while maintaining a safety profile consistent with subcutaneously delivered GLP-1RA drugs. Eli Lilly’s stock jumped up by 13.8% at market open today (17 April).

1 week ago | clinicaltrialsarena.com | Jenna Philpott |Abigail Beaney |Manasi Vaidya

The US government has signalled a major shift in its trade policies in recent weeks, with several announcements detailing plans for import tariffs. While President Trump has made several announcements on tariffs since he took office, things accelerated on 2 April, which was christened as ‘Liberation day’ when the administration announced reciprocal tariffs for a number of countries.

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Bristol Myers Squibb’s (BMS) Phase III trial investigating Camzyos (mavacamten) in patients with non-obstructive hypertrophic cardiomyopathy (nHCM) has failed to meet its dual primary endpoints. In the ODYSSEY-HCM (NCT05582395) trial, the cardiac myosin inhibitor did not show a benefit compared to placebo in either the Kansas City Cardiomyopathy Questionnaire – Clinical Summary Score (KCCQ-23 CSS) or peak oxygen consumption (pVO2) after 48 weeks.

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the drug suffered a liver injury. The oral glucagon-like peptide-1 receptor agonist (GLP-1RA) was being investigated in chronic weight management in several Phase I and Phase II trials. Two Phase I studies (NCT06567327 and NCT06568731) met pharmacokinetic (PK) endpoints and determined a formulation and dose for danuglipron.

1 week ago | clinicaltrialsarena.com | Abigail Beaney

Clinical trial costs have been rising year-on-year, with companies working to balance the scales and keep studies running despite declining investment. The pharma and biotech sector appeared to be jumping into action during the 2021 financial boom, however, this was followed by a drought of financing in the three years since. At the same time, costs have been rising for research, meaning companies who are yet to market a product are caught in the middle of a perfect storm.